Cardiac K+ channels have been recognized as potential targets for the actions of neurotransmitters, hormones and class III antiarrhythmic drugs that prolong action potential duration and refractoriness; potassium channel inhibitors can effectively prevent/inhibit cardiac arrhythmias (Li and Dong, 2010). This evidence concerns the gene KCNA3 and chronic obstructive pulmonary disease.